临床衰弱量表可预测择期胸主动脉腔内修复术后的结局:一项单中心回顾性队列研究
该单中心回顾性队列研究分析了2011年1月至2021年12月接受胸主动脉腔内修复术(TEVAR)的186例患者,以9分制临床衰弱量表(CFS)≥5分定义衰弱。衰弱患者(n=36)与非衰弱患者(n=150)的5年总生存率分别为6.2±5.5%和84.5±3.4%(p<0.001),多因素Cox回归显示CFS与总生存显著相关(HR 10.14,95%CI 5.06-20.32)。作者认为CFS是有价值的预后预测指标,对衰弱患者行TEVAR应谨慎。
要点
- 衰弱(CFS≥5分)患者TEVAR后5年总生存率仅6.2±5.5%,非衰弱患者为84.5±3.4%(p<0.001)。
- 衰弱患者30天死亡率11.1% vs 非衰弱患者0.7%(p=0.005),非居家出院率33.3% vs 4.7%(p<0.001)。
- 多因素Cox回归显示CFS与总生存显著相关(HR 10.14,95%CI 5.06-20.32)。
核心结论
- CFS是有价值的预后预测指标,对高手术风险的衰弱患者行TEVAR未能改善总生存。
- 作者认为对衰弱患者行TEVAR应谨慎。
研究设计与样本
- 单中心回顾性队列研究,分析2011年1月至2021年12月接受TEVAR的患者数据。
- 共331例患者接受TEVAR,最终纳入186例;衰弱定义为9分制CFS≥5分,衰弱组36例,非衰弱组150例。
- 主要结局为5年总生存率,次要结局包括5年无动脉瘤相关死亡生存率、术后并发症、住院时间、非居家出院率、需行动辅助、30天死亡率和再干预率。
主要发现
- 衰弱组与非衰弱组平均年龄分别为73.2±7.3岁和70.9±9.0岁(p=0.15)。
- 住院时间17(9-39)天 vs 11(10-16)天(p=0.09),再干预率8.3% vs 13.3%(p=0.58),均无显著差异。
- 衰弱组非居家出院率33.3% vs 4.7%(p<0.001),需行动辅助38.9% vs 6.0%(p<0.001),30天死亡率11.1% vs 0.7%(p=0.005)。
- 5年总生存率衰弱组6.2±5.5% vs 非衰弱组84.5±3.4%(p<0.001);中位生存时间22(6-40)个月 vs 136(87-138)个月;5年内记录死亡28例(77.8%)vs 18例(12.0%;p<0.001);5年无动脉瘤相关死亡生存率80.7%±11.2% vs 96.9%±1.5%(p=0.01)。
- 平均随访时间53.3±2.7个月;多因素Cox回归显示CFS与总生存显著相关(HR 10.14,95%CI 5.06-20.32)。
关键数值与推荐
- 衰弱定义为9分制CFS评分≥5分。
- CFS与总生存的多因素Cox回归HR为10.14(95%CI 5.06-20.32)。
临床怎么用
- 作者认为CFS是有用的预后预测指标,可用于接受TEVAR患者的预后判断。
- 作者认为对衰弱患者(CFS≥5分)行TEVAR应谨慎。
- 作者指出对衰弱患者行TEVAR未能改善总生存,其死亡归因于合并症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The Clinical Frailty Scale (CFS), used to define frail patients, is significantly associated with clinical outcomes. The CFS can predict postoperative prognosis after cardiovascular procedures. However, no reports exist on the relationship between frailty defined by the CFS and thoracic endovascular aortic repair (TEVAR) outcomes. MATERIALS AND METHODS: We analyzed data obtained from patients who underwent TEVAR between January 2011 and December 2021. Frailty was assessed using the 9-point CFS and was defined as a score of ≥5 points. The primary outcome was the 5-year overall survival rate. The secondary outcomes included the rate of freedom from aneurysm-related death at 5 years, postoperative complications, length of stay, rate of nonhome discharge, need for mobility assistance, 30-day mortality rate, and re-intervention rate. RESULTS: Of 331 patients who underwent TEVAR, 186 were included. The mean age of frail (n=36) and nonfrail (n=150) patients was 73.2 ± 7.3 years and 70.9 ± 9.0 years, respectively (p=0.15). The length of stay (17 [9-39] vs 11 [10-16] days; p=0.09) and re-intervention rate (8.3% vs 13.3%; p=0.58) were not significantly different, although frail patients had a higher rate of nonhome discharge (33.3% vs 4.7%; p<0.001), need for mobility assistance (38.9% vs 6.0%; p<0.001), and 30-day mortality (11.1% vs 0.7%; p=0.005) than nonfrail patients. The 5-year overall survival rate after TEVAR was 6.2 ± 5.5 and 84.5 ± 3.4% in frail and nonfrail patients (p<0.001). The median survival time was 22 (6-40) and 136 (87-138&x41; months, the number of recorded deaths in 5 years was 28 (77.8%) and 18 (12.0%; p<0.001), and the rate of freedom from aneurysm-related death at 5 years was 80.7%±11.2% and 96.9%±1.5% (p=0.01) in frail and nonfrail patients, respectively. The mean follow-up time was 53.3 ± 2.7 months. Multivariate Cox regression indicated that the CFS (hazard ratio, 10.14; 95% confidence interval, 5.06-20.32) was significantly associated with overall survival. CONCLUSION: The CFS is a valuable prognosis predictor, and TEVAR for frail patients with a high surgical risk could not improve the overall survival. Thoracic endovascular aortic repair in frail patients should be approached cautiously.Clinical ImpactThe Clinical Frailty Scale (CFS) could be a useful predictor of prognosis in patients undergoing thoracic endovascular aortic repair (TEVAR). A significant difference was observed between frail and nonfrail patients in the 5-year overall survival rate following TEVAR. Thoracic endovascular aortic repair for frail patients (CFS was ≥5 points) could not improve overall survival because their death was attributed to their comorbidities. Thus, TEVAR in frail patients should be approached cautiously.
引用
- Tsushima S, Shibata T, Iba Y, et al. Clinical Frailty Scale Predicts Outcomes After Elective Thoracic Endovascular Aortic Repair: A Single-Center Retrospective Cohort Study. J Endovasc Ther. 2024. PMID: 39617876. doi:10.1177/15266028241302658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。